NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

纳斯达克 · USD

Revolution Medicines, Inc. (RVMDW) 股票分析

Revolution Medicines, Inc.（RVMDW）是在纳斯达克上市的股票，以美元交易。

RVMDW

$11.70

−$0.28 (−2.34%)

2026年9月4日 · 收盘

这是一只衍生品——Revolution Medicines, Inc.（RVMD）普通股的认股权证。

发行人的基本面数据显示在发行人页面，而非本页。

查看RVMD →

价格走势

悬停查看每日收盘价。虚线表示区间起始价。

RVMDW 关键统计数据

数据截至2026年9月4日
交易
开盘价
$0.39
前收盘价
$11.98
当日波动区间
11.64–11.89
52周波动区间
11.64–11.89
成交量
38.02K
Beta系数股价相对大盘的波动幅度。1.0与大盘同步，高于1.0波动更大，低于1.0更小。
1.41

仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。

RVMDW 历年回报率

历年回报率根据每日收盘价计算。 不完整年度以浅色显示并标有星号。

年份回报率
2026 (不完整年度)+1525.00%
2025 (不完整年度)+0.00%

数据截至2026年9月4日。

最新新闻

全部9篇文章 ↓

新闻由第三方来源提供。不构成投资建议。

关于Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

公司简介以英文显示。

访问官网 →